Morgan Stanley raised AbbVie (NYSE:ABBV) price target to $181

By / / Abbvie, Morgan Stanley

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $178 to $181.

Scroll to Top